Welcome to our dedicated page for Vigil Neuroscience news (Ticker: VIGL), a resource for investors and traders seeking the latest updates and insights on Vigil Neuroscience stock.
Vigil Neuroscience, Inc. (formerly Nasdaq: VIGL) generated news as a clinical-stage biotechnology company focused on microglia and TREM2-targeted therapies for neurodegenerative diseases. Company announcements highlighted progress across its two main programs: iluzanebart, a fully human monoclonal antibody TREM2 agonist for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), and VG-3927, a novel orally bioavailable small molecule TREM2 agonist for common neurodegenerative diseases, initially Alzheimer’s disease.
News coverage for Vigil included clinical trial updates, such as data from the Phase 2 IGNITE trial of iluzanebart in ALSP and Phase 1 trial results for VG-3927, which assessed safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers, elderly participants, and Alzheimer’s disease patients. The company also reported on its ILLUMINATE natural history study in ALSP, which was designed to improve understanding of disease progression and biomarkers.
Corporate and strategic developments were another major source of news. Vigil disclosed a strategic investment from Sanofi tied to its small molecule TREM2 agonist program and later announced a definitive merger agreement under which Sanofi would acquire Vigil. Subsequent news detailed shareholder approval, litigation-related disclosure supplements, and the completion of the acquisition, after which Vigil became a wholly owned subsidiary of Sanofi.
This news archive allows readers to follow Vigil Neuroscience’s historical clinical milestones, scientific presentations at neurology-focused conferences, financing and strategic transactions, and the regulatory steps that led to its delisting and deregistration as an independent public company.
Vigil Neuroscience (VIGL) reported interim topline results from its Phase 1 clinical trial of VGL101 in healthy volunteers, establishing a foundation for a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). VGL101 demonstrated favorable safety and tolerability, with a robust reduction in cerebrospinal fluid (CSF) sTREM2 levels, indicating effective target engagement. The company is set to initiate the Phase 2 trial with a 20 mg/kg dosage this quarter, representing a significant milestone for the ALSP community.
Vigil Neuroscience (Nasdaq: VIGL) has received FDA Fast Track designation for its lead product candidate, VGL101, aimed at treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). This designation highlights the unmet medical needs of approximately 10,000 ALSP patients in the U.S. VGL101 is a TREM2 agonist currently undergoing a Phase 1 trial in healthy volunteers. The company aims to report Phase 1 topline data and initiate a Phase 2 proof-of-concept trial for VGL101 this quarter.
Vigil Neuroscience (Nasdaq: VIGL), a clinical-stage biotechnology firm, will participate in a fireside chat at the 2022 Morgan Stanley Global Healthcare Conference on September 12, 2022, at 4:50 p.m. ET. The event aims to showcase their focus on harnessing microglia for treating neurodegenerative diseases. Investors can access the live webcast through the company’s website in the 'Investors' section, with an archived replay available for 90 days post-event.
Vigil Neuroscience specializes in developing therapies to restore microglial function, addressing both rare and common diseases.
Vigil Neuroscience (Nasdaq: VIGL) announced a private investment in public equity (PIPE) financing, raising approximately $75 million by issuing 7,293,084 shares at $7.30 each and Pre-Funded Warrants for 2,980,889 shares at $7.2999. The financing is expected to close on August 16, 2022. Proceeds will support clinical development of TREM2 agonist therapies for neurodegenerative diseases. With this funding, Vigil anticipates operational plans to extend into Q1 2025. The investment was led by Deep Track Capital and included various other investors.
Vigil Neuroscience, a clinical-stage biotechnology firm (Nasdaq: VIGL), announced its participation in the 2022 Wedbush PacGrow Healthcare Virtual Conference on August 9, 2022, at 11:30 a.m. ET. The management team will engage in a fireside chat to discuss the company’s focus on microglia-targeted therapies for neurodegenerative diseases. Investors can access the live webcast through the ‘Events & Presentations’ section of Vigil's website, with an archived replay available for 90 days after the event.
The company aims to restore microglial function to develop precision-based treatments.
Vigil Neuroscience (Nasdaq: VIGL) recently presented findings at the Alzheimer's Association International Conference. Their lead product candidate, VGL101, showed promise in treating Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP). The study revealed VGL101's ability to rescue microglial dysfunction in preclinical models. A systematic review indicated a mean age of onset for ALSP symptoms at 43.2 years. The company emphasizes the importance of genetic testing due to frequent misdiagnoses as other neurodegenerative diseases.
Vigil Neuroscience (Nasdaq: VIGL) has appointed Suzanne Bruhn, Ph.D., to its Board of Directors, enhancing its leadership with over 20 years of biopharmaceutical experience. Dr. Bruhn's expertise in rare diseases and neuroscience is seen as an asset for Vigil’s mission to develop microglia-targeted therapies for neurodegenerative conditions. Notably, she has held significant roles in successful organizations, including Tiaki Therapeutics and Proclara Biosciences. This leadership change is expected to bolster Vigil's strategic direction in drug development, although it also introduces potential risks associated with transitioning leadership.
Vigil Neuroscience has received approval from the Human Research Ethics Committee in Australia to conduct a Phase 1 trial of VGL101 in healthy volunteers, allowing doses above 20 mg/kg. The FDA has also suggested considering a 30 mg/kg dose for the U.S. trial. Vigil is on track to report topline data from this trial and initiate a Phase 2 trial for ALSP in Q4 2022. The company emphasizes the favorable safety and pharmacokinetic profile of VGL101, aimed at treating neurodegenerative diseases, specifically ALSP.
Vigil Neuroscience, Inc. (Nasdaq: VIGL) has announced that CEO Ivana Magovčević-Liebisch, Ph.D., J.D., will speak at the 2022 Jefferies Global Healthcare Conference on June 8, 2022, at 2:00 p.m. ET in New York City. The event will focus on the company's commitment to leveraging microglia to develop therapies for neurodegenerative diseases. A live webcast of the discussion can be accessed through the 'Investors' section of their website, with an archived replay available for 90 days post-event.
Vigil Neuroscience (Nasdaq: VIGL) announced its Q1 2022 financial results, revealing cash and equivalents at $163.3 million, up from $91.4 million in Q4 2021. Research and development expenses rose to $10.4 million from $6.8 million year-over-year, while general and administrative expenses increased to $5.0 million from $1.2 million. The net loss for the quarter was $15.3 million compared to $8.2 million in the same period last year. Vigil continues to advance its VGL101 trial for ALSP and aims to initiate a Phase 1b trial for Alzheimer's disease in late 2022.
FAQ
What is the current stock price of Vigil Neuroscience (VIGL)?
What is the market cap of Vigil Neuroscience (VIGL)?
